Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.
rct · Level I
Where this comes from
- Record sourced from PubMed, PMID 40590452.
- Also identified by DOI 10.1093/cid/ciaf221 and PMC identifier 12249367.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a randomized clinical trial, pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA) had a better bone safety profile than tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) over 105 weeks. For individuals with low bone mineral density or other fracture risk factors, CAB-LA PrEP should be considered over TDF-based PrEP. Clinical Trials Registration. clinicaltrials.gov (NCT02720094).
Medical subject headings
- HIV Infections
- Pre-Exposure Prophylaxis
- Anti-HIV Agents
- Tenofovir
- Emtricitabine
- Pyridones
- Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination